DC Vaccine Combined With CIK Cells in Patients With Esophagus Cancer

Status Active, not recruiting

Clinical Trial Summary

The aim of this Phase I/II study is to evaluate the safety and efficacy of dendritic cells(DC) combined with cytokine-induced killer (CIK) cells in patients with advanced esophagus cancer. Experimental recombinant adenovirus coded mRNA including MUC1 and Survivin that transfected DC, which are used for DC-based immunotherapy. Based on the results of our previously performed preclinical study with DC vaccine combined with CIK cells, the researcher plan to perform the clinical trial.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02693236
Study type	Interventional
Source	Affiliated Hospital to Academy of Military Medical Sciences
Contact
Status	Active, not recruiting
Phase	Phase 1/Phase 2
Start date	August 2014
Completion date	November 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06010862` - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors	Phase 1
Completed	`NCT00201747` - Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer	Phase 2
Recruiting	`NCT06036563` - Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
Not yet recruiting	`NCT05023928` - Tumor Antigen-sensitized DC Vaccine as an Adjuvant Therapy for Esophagus Cancer	Phase 1
Recruiting	`NCT03941626` - Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies	Phase 1/Phase 2
Recruiting	`NCT04907643` - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes	N/A
Recruiting	`NCT02988921` - MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy	N/A
Terminated	`NCT02797405` - Tumour and HEalthy Tissues DOse-response and Radiosensitivity Assay	N/A
Completed	`NCT02979691` - Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01	Phase 2/Phase 3
Recruiting	`NCT03347630` - Pre-operative MRI of Esophagus Cancer	N/A
Completed	`NCT00193141` - Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer	Phase 2
Recruiting	`NCT05626309` - Clinical Trial of Qizhu Yuling Prescription in the Prevention and Treatment of Esophagus Cancer	N/A
Completed	`NCT05615129` - Sequence and Time-of-day Infusion of immunoCHemotherapy Affect Response in Oesophageal Cancer in the NeOadjuvant Setting
Recruiting	`NCT04821765` - Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer	Phase 2
Terminated	`NCT03108885` - Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence
Recruiting	`NCT04046575` - Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer	Phase 1
Recruiting	`NCT06126406` - Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors	Phase 1
Completed	`NCT03467529` - Evaluation of Full-field Coherence Tomography for ex Vivo Staging and Assessment of Superficial Esophageal Squamous Carcinoma: a Pilot Study
Completed	`NCT02552121` - Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors	Phase 1/Phase 2
Completed	`NCT02001623` - Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors	Phase 1/Phase 2